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Abstract 
Isolated leptomeningeal recurrence of melanoma is rare, occurring in 2% of patients with 
central nervous system involvement secondary to melanoma. The optimal treatment of 
leptomeningeal carcinomatosis (LMC) in melanoma has not yet been determined and 
remains a major challenge. We report a melanoma patient who presented with isolated 
LMC in the form of a new-onset weakness of the lower limbs, paresthesia of the left hand 
and foot, lumbago and headache. A lumbar puncture and spinal MRI confirmed LMC. The 
patient was treated with temozolomide 75 mg/m2/day on a 4 weeks on/2 weeks off 
schedule. After an initial transient clinical deterioration, the patient showed a complete 
radiological response as well as a dramatic improvement in quality of life. The 
encouraging clinical response reported here suggests that dose-intensified 
temozolomide might have significant activity in the treatment of leptomeningeal 
dissemination of melanoma and may be a valid treatment option for patients who have 
not been previously exposed to this agent. Moreover, this treatment regimen is 
extremely well tolerated and obviates the need for repeated intrathecal administrations 
of chemotherapeutic agents, which are often not well tolerated by patients who have 
significant co-morbidities due to their disease. As illustrated in this case, response to 
temozolomide may occur in a delayed manner, highlighting the importance of following 
temozolomide treatment long enough before determining that it is inefficient in a given 
patient. 
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Introduction 
The involvement of the central nervous system (CNS) frequently complicates the 
clinical course of malignant melanoma. Around 12–16% of all brain metastases have a 
melanomatous origin, and CNS metastases are estimated to develop in 30% of stage IV 
melanomas [1]. According to a recent series of 355 cases [2], most patients (90%) have 
parenchymal metastases whilst only a minority suffers from leptomeningeal metastases 
[2]. Leptomeningeal carcinomatosis (LMC) is defined as malignant infiltration of the pia 
mater and arachnoid membrane. LMC from melanoma is not uncommon and represents 
5–10% of all LMCs [3]. It usually occurs late in the course of disease and in the presence 
of extensive systemic dissemination or with associated brain parenchymal metastases. 
Median survival with LMC is about 4 months, and the patients’ quality of life is severely 
impaired [2]. Isolated leptomeningeal recurrence of melanoma is rare, occurring in 2% of 
patients with CNS involvement secondary to melanoma [2]. The optimal treatment of 
LMC in melanoma has not yet been determined and remains a major challenge [4]. We 
report a melanoma patient with isolated LMC showing an impressive benefit from 
systemic treatment with temozolomide. 
Case Report 
In 1996, our patient underwent local resection of a melanoma (Breslow thickness unknown) on the 
left lateral thoracic wall. At that time, he was 50 years old. Nine years later, he presented with multiple 
axillary and supraclavicular adenopathies that were treated by lymph node dissection followed by focal 
irradiation (40 Gy), as the pathology showed >40 involved lymph nodes. He was subsequently included 
in a vaccine trial with Melan-A peptide. One year later, mediastinal lymph node metastases were 
revealed by cough and chest pain, and 6 cycles of cisplatin (20 mg/m
2 on days 2–5), vinblastine (1.6 
mg/m
2 on days 1–5), dacarbazine (800 mg/m
2 on day 1) and interferon alpha (5 × 10
6 IU on days 1–5) 
were administered over the course of 6 months, leading to a complete clinical and radiological response. 
However, 3 months later, the patient presented with a new onset of weakness of the lower limbs, 
paresthesia of the left hand and foot, lumbago and headache. A brain MRI was unremarkable, while a 
spine MRI showed multiple contrast-enhancing lesions coating the entire spinal cord as well as the 
lumbar and sacral nerve roots (fig. 1a, b). A lumbar puncture confirmed LMC of the melanoma (fig. 2a, 
b). The patient was started on temozolomide 75 mg/m
2/day on a 4 weeks on/2 weeks off schedule. 
Despite this treatment, he showed a rapid initial worsening of his symptoms, and 15 days later, he 
became bedridden because of leg weakness and somnolence [Karnofsky performance index (KPS) of 
30]. He also became incontinent of urine and presented a new onset of severe bilateral deafness. Due to 
these reasons, the temozolomide treatment was discontinued, and the patient was referred to a hospice 
without further investigations. 
In the following weeks, however, he showed remarkable improvements: the bladder incontinence 
disappeared, the deafness improved and he progressively regained strength of the lower extremities. 
Temozolomide was restarted at 100 mg daily (4 weeks on/2 weeks off). Two months after starting 
temozolomide treatment, the deafness had completely recovered and the patient had regained 13 kg. He 
was able to walk without assistance (KPS 70). One month later, the spine MRI was repeated and showed 
a complete resolution of the lesions (fig. 1c, d). After 4 months of temozolomide therapy, the patient 
resumed jogging and his hobby as a glider pilot (KPS 100). Temozolomide was discontinued after 6 
months of therapy. 
Four months later, however, the patient presented with new-onset hearing loss on the left side. Brain 
and spinal MRIs confirmed extensive LMC. The patient developed difficulties swallowing, thus 
temozolomide could not be restarted. Despite subsequent treatment with intrathecal liposomal 
cytarabine (Depocyt), the patient required palliative care hospitalization and died from pneumonia 
within 3 months.  
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Discussion 
Oral temozolomide and dacarbazine (i.v.) are alkylating agents with similar activity 
against systemic melanoma [5]. In contrast to dacarbazine and other drugs used against 
melanoma, temozolomide crosses the blood-brain barrier and has been shown to induce 
clinically relevant responses in patients with cerebral metastases of melanoma [6]. 
Knowledge of patients suffering from leptomeningeal melanomatosis is limited, as these 
patients are not included in clinical trials. A complete response was reported for a patient 
with LMC from melanoma treated with a combination of oral temozolomide and 
cisplatin i.v. [7]. In the present case, we observed a complete radiological response as well 
as a dramatic improvement in quality of life with a complete recovery of autonomy and 
social activities following treatment with temozolomide alone. Interestingly, this was 
achieved after a transient severe degradation, underlying the reversibility of neurological 
defects in such a condition. The schedule of 75 mg/m
2/day (4 weeks on/2 weeks off) was 
selected to allow maximal exposition to the alkylating agent. 
The encouraging clinical response reported here suggests that dose-intensified 
temozolomide might have significant activity in the treatment of leptomeningeal 
dissemination of melanoma and may be a valid treatment option for patients who have 
not been previously exposed to this agent. Moreover, this treatment regimen is extremely 
well tolerated and obviates the need for repeated intrathecal administrations of 
chemotherapeutic agents, which are often not well tolerated by patients who have 
significant co-morbidities due to their disease. As illustrated in this case, response to 
temozolomide may occur in a delayed manner, highlighting the importance of following 
temozolomide treatment long enough before determining that it is inefficient in a given 
patient. 
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Fig. 1. Gadolinium-enhanced MRI of the cervical (a, c) and lumbar (b, d) spine. Contrast-enhancing 
lesions (arrows) are seen at the time of diagnosis of LMC (a, b). After 3 months of temozolomide 
treatment, there is complete resolution of the lesions (c, d). 
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Fig. 2. Cytology of the CSF at the time of diagnosis. a HE staining. b Immunostaining against Melan-A. 
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